ATE383426T1 - Sekretierte, virale cmv proteine verwendbar als impfstoffe und diagnostika - Google Patents

Sekretierte, virale cmv proteine verwendbar als impfstoffe und diagnostika

Info

Publication number
ATE383426T1
ATE383426T1 AT95926761T AT95926761T ATE383426T1 AT E383426 T1 ATE383426 T1 AT E383426T1 AT 95926761 T AT95926761 T AT 95926761T AT 95926761 T AT95926761 T AT 95926761T AT E383426 T1 ATE383426 T1 AT E383426T1
Authority
AT
Austria
Prior art keywords
proteins
secreted
vaccines
diagnostics
secretion
Prior art date
Application number
AT95926761T
Other languages
English (en)
Inventor
Rae Burke
Karin Hartog
Carol Pachl
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23084031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE383426(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE383426T1 publication Critical patent/ATE383426T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95926761T 1994-07-29 1995-07-21 Sekretierte, virale cmv proteine verwendbar als impfstoffe und diagnostika ATE383426T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/282,995 US6100064A (en) 1984-04-06 1994-07-29 Secreted viral proteins useful for vaccines and diagnostics

Publications (1)

Publication Number Publication Date
ATE383426T1 true ATE383426T1 (de) 2008-01-15

Family

ID=23084031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926761T ATE383426T1 (de) 1994-07-29 1995-07-21 Sekretierte, virale cmv proteine verwendbar als impfstoffe und diagnostika

Country Status (7)

Country Link
US (1) US6100064A (de)
EP (1) EP0802979B1 (de)
AT (1) ATE383426T1 (de)
AU (1) AU3103195A (de)
CA (1) CA2196097C (de)
DE (1) DE69535680T2 (de)
WO (1) WO1996004382A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162620A (en) * 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
WO1995018861A1 (en) * 1994-01-11 1995-07-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Influenza vaccine
US5965354A (en) * 1995-07-28 1999-10-12 Chiron Corporation Herpes simplex virus diagnostics
CA2360347C (en) 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
CA2433408A1 (en) * 2001-02-23 2002-08-29 Biovitrum Ab Method for purification of soluble ssao
GB2375771A (en) * 2001-05-24 2002-11-27 Univ Leeds Decellularisation of tissue implant material
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2004058166A2 (en) * 2002-12-23 2004-07-15 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
FR2862306B1 (fr) 2003-11-17 2008-05-30 Aventis Pasteur Composition vaccinale
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
EP2203184B1 (de) * 2007-09-21 2012-03-14 Sanofi Pasteur Impfstoffzusammensetzung zur prävention von cmv-infektionen
PL3009449T3 (pl) 2008-07-16 2018-09-28 Institute For Research In Biomedicine Przeciwciała neutralizujące ludzkie cytomegalowirusy i ich zastosowanie
CN102892782B (zh) 2009-12-23 2015-01-14 4-抗体股份公司 针对人类巨细胞病毒的结合成员
JP6138047B2 (ja) * 2010-10-15 2017-05-31 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サイトメガロウイルスｇＢ抗原
EP2502631A1 (de) * 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immunsuppressor und seine Verwendung
SG10201907042PA (en) 2013-10-08 2019-09-27 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
EP3031822A1 (de) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus-Antigene
AU2018331874B2 (en) * 2017-09-13 2022-06-02 Sanofi Pasteur Human cytomegalovirus immunogenic composition
JP2023547197A (ja) 2020-10-28 2023-11-09 サノフィ・パスツール Ｔｌｒ４アゴニストを含有するリポソーム、その製造および使用
EP4169513A1 (de) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Hilfsstoffzusammensetzung enthaltend sting agonisten
EP4520334A1 (de) 2023-09-07 2025-03-12 Mnemo Therapeutics Verfahren und zusammensetzungen zur verbesserung der immunreaktion
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
DE3587991T2 (de) * 1984-04-06 1995-07-20 Chiron Corp Rekombinanter herpes simplex gb-gd impfstoff.
US5194256A (en) * 1984-08-21 1993-03-16 The Board Of Trustees Of The Leland Sanford Junior University Purified human cytomegalovirus protein
DE68929478T2 (de) * 1988-01-29 2004-04-29 Aventis Pasteur Rekombinante CMV-Neutralisierungsproteine
DE69019609T2 (de) * 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
GB9203509D0 (en) * 1992-02-19 1992-04-08 British Tech Group Ibv spike protein(2)
EP0561525A1 (de) * 1992-03-04 1993-09-22 Cedars-Sinai Medical Center Verfahren zur Expression des Glycoproteins E des Herpes-Simplex-Virus-Typ 1 und Verfahren zur dessen Verwendung
GB9308963D0 (en) * 1993-04-30 1993-06-16 Smithkline Beecham Biolog Novel compounds
WO1996017938A1 (en) * 1994-12-06 1996-06-13 Bruschettini S.R.L. Glycoproteins from herpes virus and vaccines containing them

Also Published As

Publication number Publication date
CA2196097A1 (en) 1996-02-15
EP0802979A1 (de) 1997-10-29
DE69535680D1 (de) 2008-02-21
EP0802979B1 (de) 2008-01-09
AU3103195A (en) 1996-03-04
CA2196097C (en) 2007-09-11
WO1996004382A3 (en) 1996-03-21
DE69535680T2 (de) 2008-12-11
US6100064A (en) 2000-08-08
WO1996004382A2 (en) 1996-02-15

Similar Documents

Publication Publication Date Title
ATE383426T1 (de) Sekretierte, virale cmv proteine verwendbar als impfstoffe und diagnostika
ATE366314T1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
NO20000850L (no) Vaksine
MXPA96005662A (es) Vacunas de papilomavirus.
ATE245164T1 (de) Rekombinanter papillomavirus l1
DE69133228D1 (de) Dna-expressionssysteme basierend auf alphaviren
DE69835085D1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
CA2309755A1 (en) Hormone-dependent forms of the adeno-associated virus, rep proteins, dna sequences coding for them, vectors containing them, and regulatory methods of their intracellular activity
ATE393234T1 (de) Adenovirale vektoren und eine methode zur reduktion von homologer rekombination
DE3853139D1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
DE60040289D1 (de) Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff
BR9608676A (pt) Diagnóstico de, e vacinação contra vírus rna de fita positiva usando um polipeptídeo isolado não processado.
HUP9901035A2 (hu) Idegen DNS-t tartalmazó parapoxvírusok, előállításuk és alkalmazásuk vakcinákban
ATE248188T1 (de) Monoklonale antikörper gegen das epitop ypydvpdya,verfahren zu deren herstellung und ihre verwendung
ATE308618T1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
AU8405798A (en) A swine hepatitis e virus and uses thereof
ATE208421T1 (de) Stimulierung der immunantwort durch virales protein
HUP0200320A2 (hu) Macskaeredetű CD28-at, CD80-at, CD86-ot vagy CTL4-A-t expresszáló rekombináns vírusok és alkalmazásuk
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences
DE69028658D1 (de) Proteine, Vakzine und Nucleinsäuren
ATE393215T1 (de) Chimäre virus-ähnliche partikel bzw. chimäre capsomere von bpv (bovine papilloma virus)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties